{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:26:58Z","timestamp":1746736018356},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T00:00:00Z","timestamp":1518134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s12282-018-0840-1","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T11:08:16Z","timestamp":1518174496000},"page":"416-430","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical utility of RT-PCR in assessing HER 2 gene expression versus traditional IHC and FISH in breast cancer patients"],"prefix":"10.1007","volume":"25","author":[{"given":"Moushumi","family":"Suryavanshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anurag","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiten","family":"Jaipuria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dushyant","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayatri","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj Kumar","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haristuti","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mumtaz","family":"Saifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simran","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. C.","family":"Doval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhudev C.","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,9]]},"reference":[{"issue":"3","key":"840_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ctrv.2012.04.008","volume":"39","author":"SA Hurvitz","year":"2013","unstructured":"Hurvitz SA, Hu Y, O\u2019Brien N, Finn RS. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev. 2013;39(3):219\u201329.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"840_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/tbj.12277","volume":"20","author":"A Levy","year":"2014","unstructured":"Levy A, Borget I, Bahri M, Arnedos M, Rivin E, Vielh P, et al. Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients. Breast J. 2014;20(4):381\u20137.","journal-title":"Breast J."},{"issue":"33","key":"840_CR3","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","volume":"32","author":"EA Perez","year":"2014","unstructured":"Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744\u201352.","journal-title":"J Clin Oncol"},{"issue":"31","key":"840_CR4","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997\u20134013.","journal-title":"J Clin Oncol"},{"issue":"8","key":"840_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.2007.14.8197","volume":"27","author":"G Sauter","year":"2009","unstructured":"Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27(8):1323\u201333.","journal-title":"J Clin Oncol"},{"issue":"4905","key":"840_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707\u201312.","journal-title":"Science"},{"issue":"10","key":"840_CR7","first-page":"6752","volume":"7","author":"S Park","year":"2014","unstructured":"Park S, Wang HY, Kim S, Ahn S, Lee D, Cho Y, et al. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues. Int J Clin Exp Pathol. 2014;7(10):6752\u20139.","journal-title":"Int J Clin Exp Pathol."},{"issue":"2","key":"840_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ctrv.2013.09.001","volume":"40","author":"EA Perez","year":"2014","unstructured":"Perez EA, Cortes J, Gonzalez-Angulo AM, Bartlett JM. HER2 testing: current status and future directions. Cancer Treat Rev. 2014;40(2):276\u201384.","journal-title":"Cancer Treat Rev"},{"issue":"27","key":"840_CR9","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326.","journal-title":"N Engl J Med"},{"issue":"28","key":"840_CR10","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1200\/JCO.2009.26.2154","volume":"28","author":"EA Perez","year":"2010","unstructured":"Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010;28(28):4307\u201315.","journal-title":"J Clin Oncol"},{"issue":"28","key":"840_CR11","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1200\/JCO.2010.29.5071","volume":"28","author":"P De","year":"2010","unstructured":"De P, Smith BR, Leyland-Jones B. Human epidermal growth factor receptor 2 testing: where are we? J Clin Oncol. 2010;28(28):4289\u201392.","journal-title":"J Clin Oncol"},{"key":"840_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1746-1596-7-60","volume":"7","author":"H Nitta","year":"2012","unstructured":"Nitta H, Kelly BD, Padilla M, Wick N, Brunhoeber P, Bai I, et al. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections. Diagn Pathol. 2012;7:60.","journal-title":"Diagn Pathol."},{"key":"840_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1472-6890-6-2","volume":"6","author":"A Nistor","year":"2006","unstructured":"Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y. Real-time PCR complements immunohistochemistry in the determination of HER-2\/neu status in breast cancer. BMC Clin Pathol. 2006;6:2.","journal-title":"BMC Clin Pathol."},{"key":"840_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF02893412","volume":"12","author":"J Kulka","year":"2006","unstructured":"Kulka J, Tokes AM, Kaposi-Novak P, Udvarhelyi N, Keller A, Schaff Z. Detection of HER-2\/neu gene amplification in breast carcinomas using quantitative real-time PCR\u2014a comparison with immunohistochemical and FISH results. Pathol Oncol Res. 2006;12:197\u2013204.","journal-title":"Pathol Oncol Res."},{"issue":"1","key":"840_CR15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5858\/2005-129-39-CNAOCN","volume":"129","author":"SK Murthy","year":"2005","unstructured":"Murthy SK, Magliocco AM, Demetrick DJ. Copy number analysis of c-erb-B2 (HER-2\/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization. Arch Pathol Lab Med. 2005;129(1):39\u201346.","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"840_CR16","first-page":"439","volume":"6","author":"D Tvrdik","year":"2012","unstructured":"Tvrdik D, Stanek L, Skalova H, Dundr P, Velenska Z, Povysil C. Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer. Mol Med Rep. 2012;6(2):439\u201343.","journal-title":"Mol Med Rep."},{"key":"840_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707\u201312.","journal-title":"Science"},{"issue":"18S","key":"840_CR18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/jco.2007.25.18_suppl.511","volume":"25","author":"S Paik","year":"2007","unstructured":"Paik S, Kim C, Jeong J, Geyer CE, Romond EH, Mejia-Mejia O, Mamounas EP, Wickerham D, Costantino JP, Wolmark N. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3\u00a0+\u00a0and\/or FISHpositive tumors: central testing results from NSABP B-31. J Clin Oncol. 2007;25(18S):511.","journal-title":"J Clin Oncol"},{"key":"840_CR19","first-page":"25","volume":"2007","author":"PA Kaufman","year":"1009","unstructured":"Kaufman PA, Broadwater G, Lezon-Geyda K, Dressler LG, Berry D, Friedman P, Winer EP, Hudis C, Ellis MJ, Seidman AD, Harris LN. Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2\u00a0+\u00a0and HER2\u2212\u00a0metastatic breast cancer (MBC). J Clin Oncol. 1009;2007:25.","journal-title":"J Clin Oncol"},{"key":"840_CR20","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1200\/JCO.2009.26.2154","volume":"28","author":"EA Perez","year":"2010","unstructured":"Perez EA, Reinholz M, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010;28:4307\u201315.","journal-title":"J Clin Oncol"},{"key":"840_CR21","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1200\/JCO.2010.29.5071","volume":"28","author":"P De","year":"2010","unstructured":"De P, Smith BR, Leyland-Jones B. Human epidermal growth factor receptor 2 testing: where are we? J Clin Oncol. 2010;28:4289\u201392.","journal-title":"J Clin Oncol"},{"issue":"2","key":"840_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<157::AID-IJC2>3.0.CO;2-L","volume":"83","author":"P Cremoux de","year":"1999","unstructured":"de Cremoux P, Martin EC, Vincent-Salomon A, Dieras V, Barbaroux C, Liva S, et al. Quantitative PCR analysis of c-erb B-2 (HER2\/neu) gene amplification and comparison with p185(HER2\/neu) protein expression in breast cancer drill biopsies. Int J Cancer. 1999;83(2):157\u201361.","journal-title":"Int J Cancer"},{"issue":"12","key":"840_CR23","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.7314\/APJCP.2015.16.12.4959","volume":"16","author":"DC Doval","year":"2015","unstructured":"Doval DC, Sharma A, Sinha R, Kumar K, Dewan AK, Chaturvedi H, et al. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in New Delhi, India. Asian Pac J Cancer Prev. 2015;16(12):4959\u201364.","journal-title":"Asian Pac J Cancer Prev."},{"issue":"29","key":"840_CR24","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1200\/JCO.2015.61.8983","volume":"34","author":"MV Shah","year":"2016","unstructured":"Shah MV, Wiktor AE, Meyer RG, Tenner KS, Ballman KV, Green SJ, Sukov WR, Ketterling RP, Perez EA, Jenkins RB. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) results in breast cancers submitted for FISH testing: experience of a reference laboratory using us food and drug administration criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines. J Clin Oncol. 2016;34(29):3502\u201310.","journal-title":"J Clin Oncol"},{"issue":"10","key":"840_CR25","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1503\/cmaj.061011","volume":"176","author":"N Dendukuri","year":"2007","unstructured":"Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ. 2007;176(10):1429\u201334.","journal-title":"CMAJ"},{"issue":"1","key":"840_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PDM.0b013e3181e3630c","volume":"20","author":"BM Muller","year":"2011","unstructured":"Muller BM, Kronenwett R, Hennig G, Euting H, Weber K, Bohmann K, et al. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue\u2014a new option for predictive biomarker assessment in breast cancer. Diagn Mol Pathol. 2011;20(1):1\u201310.","journal-title":"Diagn Mol Pathol"},{"issue":"Suppl","key":"840_CR27","first-page":"S53","volume":"120","author":"JS Ross","year":"2003","unstructured":"Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, et al. HER-2\/neu testing in breast cancer. Am J Clin Pathol. 2003;120(Suppl):S53\u201371.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"840_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000325746","volume":"15","author":"KA Goddard","year":"2012","unstructured":"Goddard KA, Weinmann S, Richert-Boe K, Chen C, Bulkley J, Wax C. HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genom. 2012;15(1):1\u201310.","journal-title":"Public Health Genom"},{"issue":"11","key":"840_CR29","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/modpathol.2009.117","volume":"22","author":"T Khoury","year":"2009","unstructured":"Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, et al. Delay to formalin fixation effect on breast biomarkers. Mod Pathol. 2009;22(11):1457\u201367.","journal-title":"Mod Pathol"},{"issue":"11","key":"840_CR30","doi-asserted-by":"publisher","first-page":"e79901","DOI":"10.1371\/journal.pone.0079901","volume":"8","author":"Y Bai","year":"2013","unstructured":"Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, et al. Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method. PLoS One. 2013;8(11):e79901.","journal-title":"PLoS One"},{"issue":"6","key":"840_CR31","first-page":"1551","volume":"25","author":"C Tapia","year":"2004","unstructured":"Tapia C, Schraml P, Simon R, Al-Kuraya KS, Maurer R, Mirlacher M, et al. HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol. 2004;25(6):1551\u20137.","journal-title":"Int J Oncol"},{"issue":"3","key":"840_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.prp.2006.12.004","volume":"203","author":"K Egervari","year":"2007","unstructured":"Egervari K, Szollosi Z, Nemes Z. Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract. 2007;203(3):169\u201377.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"840_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1136\/jcp.47.2.117","volume":"47","author":"KY Chiu","year":"1994","unstructured":"Chiu KY, Loke SL, Ho FC. Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation. J Clin Pathol. 1994;47(2):117\u201321.","journal-title":"J Clin Pathol"},{"issue":"1","key":"840_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/path.1711730111","volume":"173","author":"F Penault-Llorca","year":"1994","unstructured":"Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 1994;173(1):65\u201375.","journal-title":"J Pathol."},{"issue":"4","key":"840_CR35","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1309\/AJCPATBZ2JFN1QQC","volume":"137","author":"J Starczynski","year":"2012","unstructured":"Starczynski J, Atkey N, Connelly Y, O\u2019Grady T, Campbell FM, di Palma S, et al. HER2 gene amplification in breast cancer: a rogues\u2019 gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. Am J Clin Pathol. 2012;137(4):595\u2013605.","journal-title":"Am J Clin Pathol"},{"key":"840_CR36","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/path.1523","volume":"202","author":"C Ginestier","year":"2004","unstructured":"Ginestier C, Charafe-Jauffret E, Penault-Llorca F, Geneix J, Adelaide J, Chaffanet M, Mozziconacci MJ, Hassoun J, Viens P, Birnbaum D, Jacquemier J. Comparative multi methodological measurement of ERBB2 status in breast cancer. J Pathol. 2004;202:286\u201398.","journal-title":"J Pathol."},{"key":"840_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1365-2559.2005.02112.x","volume":"46","author":"I Vanden Bempt","year":"2005","unstructured":"Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, Wlodarska I, Vandenberghe P, De Wolf-Peeters C. Real-time reverse transcription-PCR and fluorescence in situ hybridization are complementary to understand the mechanisms involved in HER-2\/neu overexpression in human breast carcinomas. Histopathology. 2005;46:431\u201341.","journal-title":"Histopathology"},{"key":"840_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0002-9440(10)63093-3","volume":"164","author":"M Cronin","year":"2004","unstructured":"Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004;164:35\u201342.","journal-title":"Am J Pathol"},{"key":"840_CR39","doi-asserted-by":"publisher","first-page":"8348","DOI":"10.1158\/1078-0432.CCR-05-0841","volume":"11","author":"U Vinatzer","year":"2005","unstructured":"Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res. 2005;11:8348\u201357.","journal-title":"Clin Cancer Res"},{"key":"840_CR40","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1158\/1078-0432.CCR-04-1707","volume":"11","author":"FJ Esteva","year":"2005","unstructured":"Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J, Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res. 2005;11:3315\u20139.","journal-title":"Clin Cancer Res"},{"key":"840_CR41","first-page":"4679","volume":"25","author":"C Bossard","year":"2005","unstructured":"Bossard C, Bieche I, Le Doussal V, Lidereau R, Sabourin JC. Real-timebRT-PCR: a complementary method to detect HER-2 status in breast carcinoma. Anticancer Res. 2005;25:4679\u201383.","journal-title":"Anticancer Res"},{"key":"840_CR42","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.breast.2007.05.008","volume":"16","author":"E Kostopoulou","year":"2007","unstructured":"Kostopoulou E, Vageli D, Kaisaridou D, Lidereau R, Sabourin JC. Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR. Breast. 2007;16:615\u201324.","journal-title":"Breast."},{"key":"840_CR43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1309\/1AKQDQ057PQT9AKX","volume":"129","author":"M Barberis","year":"2008","unstructured":"Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S. Quantitative analysis. Am J Clin Pathol. 2008;129:563\u201370.","journal-title":"Am J Clin Pathol"},{"key":"840_CR44","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000272953","volume":"77","author":"M Cuadros","year":"2010","unstructured":"Cuadros M, Talavera P, Lopez FJ, Garcia-Perez I, Blanco A, Concha A. Realtime RT-PCR analysis for evaluating the Her2\/neu status in breast cancer. Pathobiology. 2010;77:38\u201345.","journal-title":"Pathobiology"},{"key":"840_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12967-017-1195-7","volume":"15","author":"G Zoppoli","year":"2017","unstructured":"Zoppoli G, Garuti A, Cirmena G, Cantogno LV, Botta C, Gallo M, Ferraioli D, Carminati E, Baccini P, Curto M, Fregatti P, Isnaldi E, Lia M, Murialdo R, Friedman D, Sapino A. Ballestrero A (2017) Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases. J Transl Med. 2017;15:91.","journal-title":"J Transl Med"},{"key":"840_CR46","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1200\/JCO.2009.24.8211","volume":"28","author":"FL Baehner","year":"2010","unstructured":"Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP, Goldstein LC, Gown AM, Habel LA. Human epidermal growth factor receptor 2 assessment in a case\u2013control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol. 2010;28:4300\u20136.","journal-title":"J Clin Oncol"},{"key":"840_CR47","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1200\/JCO.2011.34.7963","volume":"29","author":"DJ Dabbs","year":"2011","unstructured":"Dabbs DJ, Klein ME, Mohsin SK, Tubbs R, Shuai Y, Bhargava R. High falsenegative rate of HER2 quantitative reverse transcription polymerase chain reaction of the oncotype DX test: an independent quality assurance study. J Clin Oncol. 2011;29:4279\u201385.","journal-title":"J Clin Oncol"},{"key":"840_CR48","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1038\/bjc.2011.135","volume":"104","author":"J Lehmann-Che","year":"2011","unstructured":"Lehmann-Che J, Amira-Bouhidel F, Turpin E, Antoine M, Soliman H, Legres L, Bocquet C, Bernoud R, Flandre E, Varna M, de Roquancourt A, Plassa LF, Giacchetti S, Espie M, de Bazelaire C, Cahen-Doidy L, Bourstyn E, Janin A, de The H, Bertheau P. Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches. Br J Cancer. 2011;104:1739\u201346.","journal-title":"Br J Cancer"},{"key":"840_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-010-1316-y","volume":"126","author":"A Noske","year":"2011","unstructured":"Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Muller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G. Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat. 2011;126:109\u201317.","journal-title":"Breast Cancer Res Treat"},{"key":"840_CR50","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/annonc\/mdu026","volume":"25","author":"G Viale","year":"2014","unstructured":"Viale G, Slaets L, Bogaerts J, Rutgers E, van\u2019t Veer L, Piccart-Gebhart MJ, de Snoo FA, Stork-Sloots L, Russo L, Dell\u2019Orto P, van den Akker J, Glas A, Cardoso F, Consortium T. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041\/BIG 03-04 MINDACT trial. Ann Oncol. 2014;25:816\u201323.","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-018-0840-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-018-0840-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-018-0840-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T03:47:31Z","timestamp":1660448851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-018-0840-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,9]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1007\/s12282-018-0840-1","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,9]]},"assertion":[{"value":"15 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they do not have any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}